alzheimersdisease
New research provides evidence that using two common Alzheimer’s disease medications together can significantly increase patients’ chances of surviving beyond five years from diagnosis. The study, published in Communications Medicine, suggests that this combined treatment could extend the lives of approximately 303,000 people with Alzheimer’s disease in the United States. Alzheimer’s disease is the most common form of dementia, characterized by progressive memory loss, cognitive decline, and behavioral changes. It affects over 50 million people worldwide and is a leading cause of death. Alzhei...
PsyPost (CA)
New research provides evidence that using two common Alzheimer’s disease medications together can significantly increase patients’ chances of surviving beyond five years from diagnosis. The study, published in Communications Medicine, suggests that this combined treatment could extend the lives of approximately 303,000 people with Alzheimer’s disease in the United States. Alzheimer’s disease is the most common form of dementia, characterized by progressive memory loss, cognitive decline, and behavioral changes. It affects over 50 million people worldwide and is a leading cause of death. Alzhei...
PsyPost (UK)
New research provides evidence that using two common Alzheimer’s disease medications together can significantly increase patients’ chances of surviving beyond five years from diagnosis. The study, published in Communications Medicine, suggests that this combined treatment could extend the lives of approximately 303,000 people with Alzheimer’s disease in the United States. Alzheimer’s disease is the most common form of dementia, characterized by progressive memory loss, cognitive decline, and behavioral changes. It affects over 50 million people worldwide and is a leading cause of death. Alzhei...
PsyPost
A panel of advisers to US health regulators backed a drug to slow Alzheimer's disease on Monday setting the stage for its expected approval for patients at an early stage of the disease. The advisers voted unanimously that the drug's benefits outweighed its risks, which include side effects like brain swelling and bleeding that will have to be monitored. "I thought the evidence was very strong in the trial showing the effectiveness of the drug," said panel member Dean Follmann, a National Institutes of Health statistician. The drug, donanemab, is from pharmaceutical company Eli Lilly and has b...
Euronews (English)
A groundbreaking study published in Acta Neuropathologica has identified a genetic variant that can reduce the risk of developing Alzheimer’s disease by up to 70%. This variant appears to help in removing toxic amyloid from the brain through the blood-brain barrier, highlighting the significant role that blood vessels in the brain may play in Alzheimer’s disease. These findings could pave the way for new therapeutic approaches to prevent or treat Alzheimer’s disease. “Alzheimer’s disease may get started with amyloid deposits in the brain, but the disease manifestations are the result of change...
PsyPost
A groundbreaking study published in Acta Neuropathologica has identified a genetic variant that can reduce the risk of developing Alzheimer’s disease by up to 70%. This variant appears to help in removing toxic amyloid from the brain through the blood-brain barrier, highlighting the significant role that blood vessels in the brain may play in Alzheimer’s disease. These findings could pave the way for new therapeutic approaches to prevent or treat Alzheimer’s disease. “Alzheimer’s disease may get started with amyloid deposits in the brain, but the disease manifestations are the result of change...
PsyPost (CA)
Researchers from the National University of Singapore have made a groundbreaking discovery about the role of a little-known protein in the brain, which could revolutionize the treatment of Alzheimer’s disease and other neurological conditions. Their study, published inCell Research, reveals that the protein Mfsd7c plays a critical role in managing choline levels in the brain, challenging previous assumptions and offering new therapeutic possibilities. Alzheimer’s disease and other neurological disorders present significant health challenges, particularly as the global population ages. Current ...
PsyPost
Researchers from the National University of Singapore have made a groundbreaking discovery about the role of a little-known protein in the brain, which could revolutionize the treatment of Alzheimer’s disease and other neurological conditions. Their study, published inCell Research, reveals that the protein Mfsd7c plays a critical role in managing choline levels in the brain, challenging previous assumptions and offering new therapeutic possibilities. Alzheimer’s disease and other neurological disorders present significant health challenges, particularly as the global population ages. Current ...
PsyPost (CA)
Researchers from the National University of Singapore have made a groundbreaking discovery about the role of a little-known protein in the brain, which could revolutionize the treatment of Alzheimer’s disease and other neurological conditions. Their study, published inCell Research, reveals that the protein Mfsd7c plays a critical role in managing choline levels in the brain, challenging previous assumptions and offering new therapeutic possibilities. Alzheimer’s disease and other neurological disorders present significant health challenges, particularly as the global population ages. Current ...
PsyPost (UK)
In a recent study published in the journal Alzheimer’s & Dementia, researchers have discovered that the connectivity between the locus coeruleus and the medial temporal lobe can be an early indicator of Alzheimer’s disease-related brain atrophy and cognitive decline. They found that lower connectivity between these brain regions during a novelty task was associated with faster atrophy in regions typically affected by Alzheimer’s disease. The motivation behind the new study stemmed from the need to understand the early mechanisms of Alzheimer’s disease, which is characterized by the accumulatio...
PsyPost (CA)
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら